Skip to main content

Diabetes

  • Hy-Vee offers vaccinations, screenings, education as part of Midwest bus tour

    WEST DES MOINES, Iowa — Hy-Vee has specially outfitted an RV to provide basic health-and-wellness services for people across the Midwest as part of a tour of the region.

  • Hamacher's Dave Wendland to moderate DSN Diabetes & Chronic Care Roundtable for 10th-consecutive year

    WAUKESHA, Wis. — Hamacher Resource Group VP Dave Wendland is moderating Drug Store News' Diabetes & Chronic Care Roundtable for the 10th-consecutive year, the company said Tuesday.

    The roundtable, part of the DSN Industry Issues Summit, will take place on Dec. 3 at the New York Athletic Club in New York and include participants like Walgreens, Thrifty-White, Costco, H-E-B, Ahold, Kerr Drug, AmerisourceBergen and McKesson/Health Mart, as well as numerous suppliers.

  • APhA Foundation project uses collaborative care to target diabetes among vulnerable populations

    WASHINGTON — A project by the philanthropic wing of the American Pharmacists Association to include pharmacists on diabetes care teams in highly affected and underserved communities has produced significant decreases in blood-sugar levels among patients, according to results released Thursday.

  • Depomed sells royalty, milestone interests in Type 2 diabetes drugs for $240.5 million

    NEWARK, Calif. — Drug maker Depomed has sold its interests in royalty and milestone payments for several Type 2 diabetes drugs to PDL BioPharma, Depomed said.

    The drug maker announced that it had sold its interest in the Type 2 diabetes therapeutic area to PDL for $240.5 million, which it plans to use to acquire rights to products it said would drive long-term growth and build on its expertise in pain and neurology.

  • NIH to investigate whether vitamin D helps prevent Type 2 diabetes

    BETHESDA, Md. — Researchers have begun the first definitive, large-scale clinical trial to investigate if a vitamin D supplement helps prevent or delay Type 2 diabetes in adults who have prediabetes and are at high risk for developing Type 2. Funded by the National Institutes of Health, the study is taking place at about 20 study sites across the United States, the agency announced Monday.

  • Vivus' Qsymia appears to cut diabetes risk in some patients

    MOUNTAIN VIEW, Calif. — Patients taking a drug used for weight loss were able to reduce their chances of developing Type 2 diabetes, according to a new study.

    According to data from a 475-patient study published in the journal Diabetes Care, Vivus' Qsymia (phentermine and topiramate) reduced the annualized incidence rate of Type 2 diabetes by up to 78.7% in high-risk, overweight or obese patients with prediabetes or metabolic syndrome. Prediabetes is a condition in which a person has elevated blood sugar and a high risk of developing Type 2 diabetes.

  • Diabetes Care Partners launches telehealth program

    WEST COVINA, Calif. — Diabetes Care Partners has introduced a new telehealth diabetes self-management education program, the company said.

    The West Covina, Calif.-based company announced the launch of DiabetesCareConnect at Eastern Plumas Health Care in Portola, Calif., supported by Telehealthdocs, a team of physicians and telemedicine specialists, and Telemed Management.

  • ADA issues new diet recommendations for diabetes patients

    NEW YORK — All people living with diabetes should make nutrition therapy part of their treatment plans, the American Diabetes Association is recommending. But the group also is saying that no single eating pattern works best for everyone.

X
This ad will auto-close in 10 seconds